Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1430511
European Journal of Endocrinology, Vol 143, Issue 4, 511-513
Copyright © 2000 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reis, A.
Right arrow Articles by Velho, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reis, A.
Right arrow Articles by Velho, G

Clinical Studies

Mutations in the insulin promoter factor-1 gene in late-onset type 2 diabetes mellitus

AF Reis, WZ Ye, D Dubois-Laforgue, C Bellanne-Chantelot, J Timsit, and G Velho

INSERM Unite 342, Institut Cochin de Genetique Moleculaire, Paris, France.

OBJECTIVE: Insulin promoter factor-1 (IPF-1) is a transcription factor expressed in pancreatic beta cells. Following the identification of missense variants in the coding regions of the IPF-1 gene, in subjects selected for a strong family history of type 2 diabetes, the aim of our study was to evaluate the prevalence of these variants in the common form of type 2 diabetes. METHODS: Three variants (C18R, Q59L and D76N) were screened by PCR-RFLP in a group of 296 unrelated French late-onset type 2 diabetic subjects consecutively recruited in a diabetes department of a university hospital, regardless of family history of diabetes. RESULTS: The C18R and Q59L variants were each found in 0.37% of the diabetic patients, and in none of 147 controls. We did not detect the D76N variant, which was the most frequent variant in subjects with a strong family history of diabetes, in patients or controls. CONCLUSIONS: We have observed a combined prevalence of missense variants in the coding region of the IPF-1 gene of around 1%, in unselected patients with the common form of late-onset type 2 diabetes. The prevalence of these variants in subjects with a strong family history of type 2 diabetes had been found to be as high as approximately 6%. These differences in prevalence might be related to differences in the clinical profile of patients, such as age of onset of diabetes and associated obesity, as well as a family history of diabetes.


This article has been cited by other articles:


Home page
DiabetesHome page
S. C. Elbein, X. Wang, M. A. Karim, B. I. Freedman, D. W. Bowden, A. R. Shuldiner, F. L. Brancati, and W. H. L. Kao
Role of a Proline Insertion in the Insulin Promoter Factor 1 (IPF1) Gene in African Americans With Type 2 Diabetes.
Diabetes, October 1, 2006; 55(10): 2909 - 2914.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
S. C. Elbein and M. A. Karim
Does the Aspartic Acid to Asparagine Substitution at Position 76 in the Pancreas Duodenum Homeobox Gene (PDX1) Cause Late-Onset Type 2 Diabetes?
Diabetes Care, August 1, 2004; 27(8): 1968 - 1973.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 European Society of Endocrinology.